Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure?

Current Cardiovascular Risk Reports

Volumn 1, Issue 3, 2007, Pages 198-203

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49449094209     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-007-0032-6     Document Type: Article

References (42)

1. La Rosa JC: Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001, 88: 291-293.
2. Sierra C, de la Sierra Alejandro: Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Curr Opin Nephrol Hypertens 2005, 14: 435-441.
3. Cholesterol Treatment Trialists' Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005, 366: 1267-1278.
4. Pilote L, Abrahamowicz M, Rodrigues E, et al.: Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?Ann Intern Med 2004, 141: 102-112.
5. Verdecchia P, Reboldi G, Angeli F, et al.: Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005, 46: 386-392.
6. Jafar TH, Stark PC, Schmid CH, et al.: Progression of chronic kidney diseases: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Ann Int Med 2003, 139: 244-252.
7. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342: 145-153.
8. Wing LM, Reid CM, Ryan P, et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly: Second Australian National Blood Pressure Study Group. N Engl J Med 2003, 348: 583-592.
9. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353: 611-616.
10. Fox KM, European trial on reduction of cardiac events with perindoprol in stable coronary artery disease investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362: 782-788.
11. Turnbull F, Neal B, Pfeffer M, et al.: Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007, 25: 951-958.
12. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345: 861-869.
13. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345: 851-860.
14. Schrader J, Lüders S, Kulchewski A, et al.: Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005, 36: 1218-1224.
15. Dahlöf B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endopoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol: the LIFE Study Group. Lancet 2002, 359: 995-1003.
16. Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356: 366-372.
17. Malacco E, Marcia G, Rappelli A, et al.: Treatment of isolated systolic hypertension: the SHELL study results: the SHELL Investigators. Blood Press 2003, 12: 160-167.
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288: 2981-2997.
19. Julius S, Kjeldsen S, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsart an or amlodipine: the VALUE randomised trial. Lancet 2004, 363: 2022-2031.
20. Zanchetti A, Bond MG, Hennig M, et al.: Calcium-antagonist lacidipine slows down progression of asymptom atic carotid atherosclerosis. Circulation 2002, 106: 2422-2427.
21. Staessen JA, Wang JG, Thijs L: Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003, 21: 1055-1076.
22. Turnbull F: Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362: 1527-1535.
23. Turnbull F, Neal B, Algert C, et al.: Effects of different blood-pressure lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005, 165: 1410-1419.
24. Sica DA: Angiotensin-converting enzyme inhibitors. In Clinical Hypertension: A Companion to Braunwald's Heart Disease, edn 1. Edited by Black H, Elliott W. Philadelphia: Elsevier, Inc.; 2006: 239-253.
25. Wenzel UO: Angiotensin-converting enzyme inhibitors and progression of renal diseases: evidence from clinical studies. Contrib Nephrol 2001, 135: 200-211.
26. Garcia-Donaire JA, Segura J, Ruilope LM: Clinical trials in nephrology: success or failure. Curr Opin Nephrol Hypertens 2007, 16: 59-63.
27. Casas JP, Chua W, Loukogeorgakis S, et al.: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 366: 2026-2033.
28. Lewis EJ: Treating hypertension in the patient with overt diabetic nephropathy. Semin Nephrol 2007, 27: 182-194.
29. Berl T, Hunsicker LG, Lewis JB, et al.: Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005, 16: 2170-2179.
30. Wiysonge CS, Bradley H, Mayosi BM, et al.: Beta-blockers for hypertension. Cochrane Database Syst Rev 2007, 1: CD002003.
31. Sica DA: Impact of antihypertensive therapy on the ratepressure product: the role of chronother apeutics. Eur Heart J 1999, 1(Suppl B): B24-B33.
32. White WB: How well does ambulatory blood pressure predict target-organ disease and clinical outcome in patients with hypertension?Blood Press Monit 1999, 4(Suppl 2): S17-S21.
33. Svensson P, de Faire U, Sleight P, et al.: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001, 38: E28-E32.
34. Berkels R, Taubert D, Rosenkranz A, Rosen R: Vascular protective effects of dihydropyridine calcium antagonists. Involvement of endothelial nitric oxide. Pharmacology 2003, 69: 171-176.
35. Sever PS, Poulter NR, Elliott WJ, et al.: Blood pressure reduction is not the only determinant of outcome. Circulation 2006, 113: 2754-2574.
36. Weinberger J: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack: PROGRESS Collaborative Group. Lancet 2001, 358: 1033-1041.
37. Hansson L, Hedner T, Lund-Johansen P, et al.: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) Study. Lancet 2000, 356: 359-365.
38. Braunwald E, Domanski MJ, Fowler SE, et al.: Angiotensin-converting-enzyme inhibition in stable coronary artery disease: the PEACE Trial Investigators. N Engl J Med 2004, 351: 2058-2068.
39. Solomon SD, Rice MM, Jablonski K, et al.: Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006, 114: 26-31.
40. Lewington S, Clarke R, Qizilbash N: Age-specific relevance of usual blood pressure to vascular mortality: ameta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360: 1903-1913.
41. Devereux RB, Dahlof B: Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Curr Med Res Opin 2007, 23: 443-457.
42. Sica DA: Class effects of angiotensin-converting enzyme inhibitors. Am J Managed Care 2000, 6: S85-S108.